Skip to main content
HairCited

Minoxidil için Alopecia Areata

A

48 çalışmaya (2 meta-analyses, 1 RCT), toplam 21,842 katılımcıyla dayanmaktadır. 37/48 çalışma olumlu etkiler göstermektedir.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dminoxidil\u0026condition\u003Dalopecia\u002Dareata'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

Sonuç

Minoxidil has strong evidence supporting its use for alopecia areata, with the majority of studies showing positive effects, and is widely used as both a topical and oral option for this condition.

  • 37 out of 48 studies show positive effects across a large pool of 21,842 participants
  • Available in topical (2% and 5%) and oral low-dose formulations
  • Extends the hair growth phase and increases blood supply to hair follicles
  • Often used in combination with other treatments like corticosteroids for enhanced effectiveness

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None Etki: None None

Popülasyon: women with androgenetic alopecia (female pattern hair loss)

Case Reports n=1
Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case …
Dose: None vs: None Outcome: hair regrowth in severe alopecia areata Etki: None None

Popülasyon: patient with severe alopecia areata with suboptimal response to tofacitinib

review
Oral Minoxidil for Alopecia Treatment: Risks, Benefits, and Recommendations.
Dose: Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 vs: Placebo Etki: Comparable efficacy to topical minoxidil; hypertrichosis 24%, shedding 16-22%, peripheral edema 2% None
Review
Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities.
Dose: None vs: None Outcome: None Etki: None None

Popülasyon: None

review
The Use of Light-Based Therapies in the Treatment of Alopecia.
Dose: Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri vs: Placebo Etki: LLLT improves hair density in AGA; potential to prolong anagen phase in telogen effluvium; may promo None
retrospective cohort study n=321
Asynchronous Teledermatology for Non-Scarring Alopecia: A Retrospective Study.
Dose: Minoxidil (OTC) and clobetasol for mild cases; prescription medications for moderate-severe. Specifi vs: Placebo Etki: 91.3% received definitive remote diagnosis; only 8.7% required in-person follow-up. AA most common ( None

Key Statistics

122

Çalışmalar

27416

Katılımcılar

Positive

A

Derece

Referenced Papers

Dermatologic clinics 2025 5 atıf
Pediatric dermatology 2025 5 atıf
Journal of the … 2025 2 atıf
Journal of clinical … 2025 1 atıf
Archives of dermatological … 2025
International journal of … 2024 39 atıf
American family physician 2024 8 atıf
Skin health and … 2024 7 atıf
Archives of dermatological … 2023 16 atıf
The Cochrane database … 2023 2 atıf
The Journal of … 2022 170 atıf
Journal of the … 2022 90 atıf
Skin appendage disorders 2022 7 atıf
Journal of dermatological … 2021 51 atıf
International journal of … 2020 58 atıf
The journal of … 2020 3 atıf
The Australasian journal … 2019 152 atıf
American journal of … 2019 84 atıf
Expert opinion on … 2019 34 atıf
Klinicka onkologie : … 2019 11 atıf
Journal of the … 2018 114 atıf
Dermatology online journal 2018
American family physician 2017 141 atıf
Actas dermo-sifiliograficas 2017 17 atıf
Deutsches Arzteblatt international 2016 99 atıf
Current problems in … 2015 322 atıf
Canadian family physician … 2015 31 atıf
The journal of … 2015 25 atıf
Current problems in … 2015 18 atıf
Der Internist 2015
American journal of … 2014 82 atıf
Expert opinion on … 2014 57 atıf
Giornale italiano di … 2014 18 atıf
Giornale italiano di … 2014
International journal of … 2013 61 atıf
Recent patents on … 2011 6 atıf
Seminars in cutaneous … 2009 85 atıf
American family physician 2009
The Cochrane database … 2008 222 atıf
Current opinion in … 2008 31 atıf
International journal of … 2007 185 atıf
Alopecia areata. Case Report
Dermatology nursing 2007
The Australasian journal … 2006
Journal of the … 2005 44 atıf
Cleveland Clinic journal … 2005
Praxis 2003 28 atıf
American family physician 2003 2 atıf
American family physician 2003
American journal of … 2000 28 atıf
International journal of … 1999 16 atıf
Dermatologic clinics 1998 121 atıf
American family physician 1990
Dermatologic clinics 1987
Journal of the … 1984 122 atıf
Journal of the … 1984
Archives of dermatology 1984

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Yaygın Kullanılan Dozajlar

topical:
2-5% solution, twice daily

Üst sınır: 5% topical solution

Araştırmalarda İncelenen Dozajlar

Dozaj Süre Etki N
None -- Neutral --
None -- Positive 1
Oral minoxidil: women 1.25 mg/day starting dose (range 0.625-5 mg/day); men 2.5 mg/day (range 1.25-5 -- Positive --
None -- Mixed --
Low-level light therapy (LLLT) various devices and wavelengths; combined with minoxidil or finasteri -- Positive --
Minoxidil (OTC) and clobetasol for mild cases; prescription medications for moderate-severe. Specifi -- Positive 321
None -- Mixed --
None -- Mixed 1

En iyi alım zamanı: Apply to dry scalp morning and evening, at least 4 hours before bed

Safety & Side Effects

Bildirilen Yan Etkiler

  • Scalp irritation and dryness
  • Initial shedding phase (first 2-8 weeks)
  • Unwanted facial hair growth (especially in women)
  • Dizziness or lightheadedness (rare with topical use)
  • Heart palpitations (rare, more common with oral form)

Bilinen Etkileşimler

  • Antihypertensive medications (additive blood pressure lowering)
  • Topical corticosteroids (may increase absorption)
  • Retinoids (tretinoin may enhance penetration and side effects)

Tolere edilebilir üst alım: 5% topical solution

Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.

Frequently Asked Questions

Does Minoxidil help with Alopecia Areata?
Based on 122 studies with 27,416 participants, there is strong evidence from multiple clinical trials that Minoxidil may support Alopecia Areata management. Our evidence grade is A (Strong Evidence).
How much Minoxidil should I take for Alopecia Areata?
Studies have used various dosages. A commonly studied range is 2-5% solution, twice daily. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Minoxidil?
Reported side effects may include Scalp irritation and dryness, Initial shedding phase (first 2-8 weeks), Unwanted facial hair growth (especially in women), Dizziness or lightheadedness (rare with topical use). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Minoxidil and Alopecia Areata?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 122 peer-reviewed studies with 27,416 total participants. The overall direction of effect is positive.

Related Evidence

FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.